MedTrace Logo

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

NCT07175389 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2025-09-16

No results posted yet for this study

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Serplulimab in patients with pancreatic cancer after standard treatment failure.

Conditions

  • Refractory Pancreatic Ductal Adenocarcinoma
  • Refractory Pancreatic Adenocarcinoma

Interventions

DRUG

JDB153

JDB153 is administered orally at doses of 600 mg twice daily (1200 mg total daily dose) or 500 mg twice daily (1000 mg total daily dose) based on safety and tolerability assessment.

DRUG

Serplulimab

Serplulimab is administered by intravenous infusion at a dose of 200 mg once every 3 weeks (Q3W).

Sponsors & Collaborators

  • West China Hospital

    lead OTHER

Principal Investigators

  • Dan Cao, MD · Division of Abdominal Tumor, Department of Medical Oncology, Cancer Center and State Key Laboratory of Biological Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-01
Primary Completion
2027-09-01
Completion
2027-10-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07175389 on ClinicalTrials.gov